News and blogs
175 results found.
This week I’ve analysed 18,000 genes!
We spoke to Dr Amir Enshaei to find out how his research will reduce the long-term side effects of treatment for children with blood cancer.
Discovery could treat childhood blood cancers
Genetic mutations that drive the development of childhood leukaemia can be traced to errors by the immune system during the production of antibodies.
Leukaemia treatment: test could predict response
The first test to quickly and accurately predict how people will respond to standard treatment for the most common type of leukaemia has been developed.
CAR-T access in Scotland for childhood leukaemia
Children and young people in Scotland with ALL who relapse after standard treatments will be able to access the CAR-T cell therapy Kymriah.
Two breakthroughs in CAR-T therapy
First child with acute lymphoblastic leukaemia (ALL) receives CAR-T therapy on the NHS and the treatment is made available to adult lymphoma patients.
How a virus can lead to lymphoma trial
Our researcher has been investigating how a virus that causes lymphoma increases the production of this cancer-driving microRNA. Find out more.
Blood Cancer UK research highlights 2018
From CAR-T therapy to a new understanding of how leukaemia develops in children. We look back at some of the breakthroughs our supporters help us fund.
How gene mutations cause blood cancers
Blood Cancer UK scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers.
New leukaemia treatment in Scotland
A targeted drug that improves survival for people with an aggressive type of blood cancer will be made available on the NHS in Scotland.
CAR-T therapies hold promise for cancers
Immunotherapy treatments called CAR-T therapies involve reprogramming a type of ‘supercharged’ immune cell could be mass-produced to help fight cancer.
Through the eye of a needle: Molecular immunology and anti-cancer drugs
Finding drugs that can target cancer cells but leave healthy cells unharmed is an ongoing problem in cancer research. At the University of Oxford, Professor Terry Rabbitts is exploring ways to create targeted drugs that work by blocking blood cancer proteins from interacting with healthy proteins – and the technique he’s developed for making these drugs could also have an impact on many other diseases. Read on to find out more…
CAR-T treatment turned down on NHS
The NHS medicines watchdog has recommended that a treatment called Kymriah should not be available to people with diffuse large B-cell lymphoma (DLBCL).
Blood cancer patients least likely to understand their diagnosis
How MPN disrupt work of blood stem cells
Blood Cancer UK researchers discover blood stem cells need to strike a delicate balance between making other types of blood cells and renewing themselves.
CLL - more people to benefit from ibrutinib in future
More people living with a type of leukaemia in England will soon have access to Ibrutinib, thanks to a successful campaign by Blood Cancer UK.
Blood cancers have longer diagnosis
A survey of patients treated for cancer on the NHS in England shows that blood cancers are still taking longer to be diagnosed than other types of cancer.
Blood cancer research breakthroughs
We look back on some of the biggest developments in blood cancer research that have led to improved NHScare for people with blood cancer.
Stem cell transplants without chemotherapy?
One option for treating or even curing blood cancers is a stem cell transplant. What if there was a less toxic way to get rid of these stem cells?
Leukaemia risk: babies with Down's syndrome
Professor Irene Roberts explains why new guidelines are needed to identify those children with Down's syndrome at risk of developing leukaemia.
New drug to improve leukaemia survival rates
A targeted cancer drug that reduces the chances of relapse for people with an aggressive type of leukaemia will be made available on the NHS in Scotland.